SCHEMBL5084989

SCHEMBL5084989

CCCCOC(=O)NC(C(=O)O)c1ccc(OCCN2CCN(C)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.52
ITGA2B P08514 1/20 0.52
THRA P10827 1/20 0.50
THRB P10828 1/20 0.50
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RAB9A P51151 2/20 0.47
GAA P10253 1/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LTA4H P09960 2/20 0.46
NPC1 O15118 1/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.45
HRH2 P25021 3/20 0.44
HRH1 P35367 3/20 0.44
FAAH O00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5227540 0.92 KDM4E (0.56) ITGB3ITGA2BTHRATHRBMAPK1
SCHEMBL4687657 0.90 ALDH1A1 (0.55) THRATHRBMAPK1SMN1; SMN2RAB9A
SCHEMBL3376481 0.85 HRH2 (0.48) ITGB3ITGA2BRAB9AALDH1A1KDM4E
SCHEMBL3376479 0.85 HRH2 (0.48) ITGB3ITGA2BRAB9AALDH1A1KDM4E
SCHEMBL3376486 0.85 HRH2 (0.48) ITGB3ITGA2BRAB9AALDH1A1KDM4E
SCHEMBL4686341 0.83 SMN1; SMN2 (0.60) MAPK1SMN1; SMN2RAB9AL3MBTL1NPC1
SCHEMBL5505866 0.82 SMN1; SMN2 (0.56) MAPK1SMN1; SMN2RAB9AL3MBTL1NPC1
SCHEMBL3645386 0.82 SMN1; SMN2 (0.56) MAPK1SMN1; SMN2RAB9AL3MBTL1NPC1
SCHEMBL4683920 0.81 SMN1; SMN2 (0.58) MAPK1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL4685989 0.80 ALDH1A1 (0.48) MAPK1SMN1; SMN2RAB9AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008101840-A1 COMBINATION OF ERLOTINIB AND MEK-INHIBITORS FOR INHIBITING PROLIFERATION OF TUMOR CELLS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-28 WO disclosed